Filters

Agnès Linglart, Helena Fryssira, Olaf Hiort, Paul-Martin Holterhus, Guiomar Perez de Nanclares, Jesús Argente, Claudine Heinrichs, Alma Kuechler, Giovanna Mantovani, Bruno Leheup, Philippe Wicart, Virginie Chassot, Dorothée Schmidt, Óscar Rubio-Cabezas, Annette Richter-Unruh, Sara Berrade, Arrate Pereda, Emese Boros, Maria Teresa Muñoz-Calvo, Marco Castori, Yasemin Gunes, Guylene Bertrand, Pierre Bougnères, Eric Clauser, Caroline Silve

The Journal of clinical endocrinology and metabolism 2013;97(12):E2328-38

Full Text

Abstract

Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.

Robert W Colman, Wei Zhang

Blood 2007;110(5):1475-82

Free Full Text

Abstract

A large-sample assessment of possible association between ischaemic stroke and rs12188950 in the PDE4D gene.

Håkan Lövkvist, Sandra Olsson, Peter Höglund, Olle Melander, Christina Jern, Marketa Sjögren, Gunnar Engström, J Gustav Smith, Bo Hedblad, Gunnar Andsberg, Hossein Delavaran, Katarina Jood, Ulf Kristoffersson, Holger Luthman, Bo Norrving, Arne Lindgren

European journal of human genetics : EJHG 2012;20(7):783-9

Free Full Text

Abstract

Results: 1 – 14 / 14

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Cyclic Nucleotide Phosphodiesterases, Type 3""[mesh_terms]

Intracellular leptin-signaling pathways in hypothalamic neurons: the emerging role of phosphatidylinositol-3 kinase-phosphodiesterase-3B-cAMP pathway.

Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?

Phosphodiesterase III inhibitors for heart failure.

The function of vascular smooth muscle phosphodiesterase III is preserved in healthy human aging.

Interactions between inotropic drugs.

The therapeutic potential of novel cardiotonic agents.

COX inhibitors downregulate PDE4D expression in a clinical model of inflammatory pain.

Live Cell Monitoring of Phosphodiesterase Inhibition by Sulfonylurea Drugs.

Cilostazol in the management of vascular disease.

Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.

The prophylactic use of the beta-blocker esmolol in combination with phosphodiesterase III inhibitor enoximone in elderly cardiac surgery patients.

PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct syndromes with or without GPCR-signaling hormone resistance.

Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.

A large-sample assessment of possible association between ischaemic stroke and rs12188950 in the PDE4D gene.

Results for

""Cyclic Nucleotide Phosphodiesterases, Type 3""[mesh_terms]